- Home
- MTVA vs NRXS Comparison
MTVA vs NRXS Comparison
Compare MTVA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- NRXS
- Stock Information
- Founded
- MTVA 2014
- NRXS 2011
- Country
- MTVA United States
- NRXS United States
- Employees
- MTVA N/A
- NRXS N/A
- Industry
- MTVA
- NRXS
- Sector
- MTVA
- NRXS
- Exchange
- MTVA NYSE
- NRXS Nasdaq
- Market Cap
- MTVA 18.9M
- NRXS 17.3M
- IPO Year
- MTVA N/A
- NRXS 2023
- Fundamental
- Price
- MTVA $1.85
- NRXS $2.42
- Analyst Decision
- MTVA
- NRXS
- Analyst Count
- MTVA 0
- NRXS 0
- Target Price
- MTVA N/A
- NRXS N/A
- AVG Volume (30 Days)
- MTVA 256.5K
- NRXS 25.4K
- Earning Date
- MTVA 11-07-2024
- NRXS 11-12-2024
- Dividend Yield
- MTVA N/A
- NRXS N/A
- EPS Growth
- MTVA N/A
- NRXS N/A
- EPS
- MTVA N/A
- NRXS N/A
- Revenue
- MTVA N/A
- NRXS $2,456,219.00
- Revenue This Year
- MTVA N/A
- NRXS $383.16
- Revenue Next Year
- MTVA N/A
- NRXS N/A
- P/E Ratio
- MTVA N/A
- NRXS N/A
- Revenue Growth
- MTVA N/A
- NRXS N/A
- 52 Week Low
- MTVA $1.55
- NRXS $2.00
- 52 Week High
- MTVA $6.75
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- NRXS 42.11
- Support Level
- MTVA N/A
- NRXS $2.72
- Resistance Level
- MTVA N/A
- NRXS $2.77
- Average True Range (ATR)
- MTVA 0.00
- NRXS 0.43
- MACD
- MTVA 0.00
- NRXS -0.05
- Stochastic Oscillator
- MTVA 0.00
- NRXS 12.71
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).